Faye Elliott

ORCID: 0000-0002-3239-6914
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Colorectal Cancer Treatments and Studies
  • Radiomics and Machine Learning in Medical Imaging
  • Cancer Treatment and Pharmacology
  • Genetic factors in colorectal cancer
  • Cutaneous Melanoma Detection and Management
  • Colorectal Cancer Screening and Detection
  • Lung Cancer Treatments and Mutations
  • Bladder and Urothelial Cancer Treatments
  • Skin Protection and Aging
  • Melanoma and MAPK Pathways
  • Vitamin D Research Studies
  • Medical Imaging Techniques and Applications
  • Gastric Cancer Management and Outcomes
  • Colorectal and Anal Carcinomas
  • melanin and skin pigmentation
  • Nonmelanoma Skin Cancer Studies
  • Urinary and Genital Oncology Studies
  • Cancer Genomics and Diagnostics
  • DNA Repair Mechanisms
  • Bone and Dental Protein Studies
  • Cancer Immunotherapy and Biomarkers
  • Molecular Biology Techniques and Applications
  • Allergic Rhinitis and Sensitization
  • Nail Diseases and Treatments
  • Cancer Diagnosis and Treatment

University of Leeds
2015-2025

St James's University Hospital
2013-2023

Institute of Molecular Medicine
2008-2023

Wellcome Trust
2023

Cancer Research And Biostatistics
2011-2016

Leeds Teaching Hospitals NHS Trust
2009-2012

Cancer Research UK
2007-2012

In-Q-Tel
2012

Royal Surrey County Hospital
2009-2012

University of Surrey
2012

Activating mutation of the KRAS oncogene is an established predictive biomarker for resistance to anti-epidermal growth factor receptor (anti-EGFR) therapies in advanced colorectal cancer (aCRC). We wanted determine whether and/or BRAF also a other aCRC therapies.The Medical Research Council Fluorouracil, Oxaliplatin and Irinotecan: Use Sequencing (MRC FOCUS) trial compared treatment sequences including first-line fluorouracil (FU), FU/irinotecan or FU/oxaliplatin aCRC. Tumor blocks were...

10.1200/jco.2009.22.4295 article EN Journal of Clinical Oncology 2009-11-03

Lynch syndrome is associated with an increased risk of colorectal cancer and a broader spectrum cancers, especially endometrial cancer. In 2011, our group reported long-term outcomes (mean follow-up 55·7 months [SD 31·4]) for participants enrolled into randomised trial daily aspirin versus placebo. This report completes the planned 10-year to allow longer-term assessment effect taking regular in this high-risk population.

10.1016/s0140-6736(20)30366-4 article EN cc-by The Lancet 2020-06-01

Observational and epidemiologic data indicate that the use of aspirin reduces risk colorectal neoplasia; however, effects in Lynch syndrome (hereditary nonpolyposis colon cancer) are not known. Resistant starch has been associated with an antineoplastic effect on colon.In a randomized, placebo-controlled trial, we used two-by-two design to investigate aspirin, at dose 600 mg per day, resistant (Novelose), 30 g reducing adenoma carcinoma among persons syndrome.Among 1071 43 centers, 62 were...

10.1056/nejmoa0801297 article EN New England Journal of Medicine 2008-12-10

A cohort study was carried out to test the hypothesis that higher vitamin D levels reduce risk of relapse from melanoma.A pilot retrospective 271 patients with melanoma suggested may protect against recurrence melanoma. We tested these findings in a survival analysis 872 recruited Leeds Melanoma Cohort (median follow-up, 4.7 years).In study, self-reports taking supplements were nonsignificantly correlated reduced (odds ratio = 0.6; 95% CI, 0.4 1.1; P .09). Nonrelapsers had mean...

10.1200/jco.2009.22.1135 article EN Journal of Clinical Oncology 2009-09-22

Purpose Candidate predictive biomarkers for irinotecan and oxaliplatin were assessed in 1,628 patients Fluorouracil, Oxaliplatin, CPT-11: Use Sequencing (FOCUS), a large randomized trial of fluorouracil alone compared with advanced colorectal cancer. Methods The candidate were: tumor immunohistochemistry MLH1/MSH2, p53, topoisomerase-1 (Topo1), excision repair cross-complementing gene 1 (ERCC1), O-6-methylguanine-DNA-methyltranserase (MGMT), cyclooxygenase 2 (COX2); germline DNA...

10.1200/jco.2007.15.5580 article EN Journal of Clinical Oncology 2008-05-28

Abstract Evidence supporting aspirin and resistant starch (RS) for colorectal cancer prevention comes from epidemiologic laboratory studies (aspirin RS) randomized controlled clinical trials (aspirin). Familial adenomatous polyposis (FAP) strikes young people and, untreated, confers virtually a 100% risk of early death. We conducted an international, multicenter, randomized, placebo-controlled trial (600 mg/d) and/or RS (30 g/d) 1 to 12 years prevent disease progression in FAP patients 10 21...

10.1158/1940-6207.capr-11-0106 article EN Cancer Prevention Research 2011-05-01

Abstract Radical radiotherapy and surgery achieve similar cure rates in muscle-invasive bladder cancer, but the choice of which treatment would be most beneficial cannot currently predicted for individual patients. The primary aim this study was to assess whether expression any a panel DNA damage signaling proteins tumor samples taken before irradiation could used as predictive marker response, or rather prognostic. Protein MRE11, RAD50, NBS1, ATM, H2AX studied by immunohistochemistry...

10.1158/0008-5472.can-10-1202 article EN Cancer Research 2010-09-14

European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene.

10.1093/hmg/ddr303 article EN Human Molecular Genetics 2011-07-12
Alexi Archambault Yu‐Ru Su Jihyoun Jeon Minta Thomas Yi Lin and 95 more David V. Conti Aung Ko Win Lori C. Sakoda Iris Lansdorp‐Vogelaar Elisabeth F. P. Peterse Ann G. Zauber David Duggan Andreana N. Holowatyj Jeroen R. Huyghe Hermann Brenner Michelle Cotterchio Stéphane Bézieau Stephanie L. Schmit Christopher K. Edlund Melissa C. Southey Robert J. MacInnis Peter T. Campbell Jenny Chang‐Claude Martha L. Slattery Andrew T. Chan Amit D. Joshi Mingyang Song Yin Cao Michael O. Woods Emily White Stephanie J. Weinstein Cornelia M. Ulrich Michael Hoffmeister Stephanie A. Bien Tabitha A. Harrison Jochen Hampe Christopher I. Li Clemens Schafmayer Kenneth Offit Paul D.P. Pharoah Vı́ctor Moreno Annika Lindblom Alicja Wolk Anna H. Wu Li Li Marc J. Gunter Andrea Gsur Temitope O. Keku Rachel Pearlman D. Timothy Bishop Sergi Castellví‐Bel Leticia Moreira Pavel Vodička Ellen Kampman Graham G. Giles Demetrius Albanes John A. Baron Sonja I. Berndt Stefanie Brezina Stephan Buch Daniel D. Buchanan Antonia Trichopoulou Gianluca Severi María‐Dolores Chirlaque María‐José Sánchez Domenico Palli Tilman Kühn Neil Murphy Amanda J. Cross Andrea N. Burnett‐Hartman Stephen J. Chanock Albert de la Chapelle Douglas F. Easton Faye Elliott Dallas R. English Edith J. M. Feskens Liesel M. FitzGerald Phyllis J. Goodman John L. Hopper Thomas J. Hudson David J. Hunter Eric J. Jacobs Corinne E. Joshu Sébastien Küry Sanford D. Markowitz Roger L. Milne Elizabeth A. Platz Gad Rennert Hedy S. Rennert Fredrick R. Schumacher Robert S. Sandler Daniela Seminara Catherine M. Tangen Stephen N. Thibodeau Amanda E. Toland Fränzel J.B. van Duijnhoven Kala Visvanathan Ludmila Vodičková John D. Potter Satu Männistö

10.1053/j.gastro.2019.12.012 article EN Gastroenterology 2019-12-19

<h3>Importance</h3> <i>RAS</i>wild-type (wt) status is necessary but not sufficient for response to anti-epidermal growth factor receptor (EGFR) agents in advanced colorectal cancer (aCRC). RNA expression of EGFR ligands epiregulin (EREG) and amphiregulin (AREG) may correlate with EGFR-targeted therapy efficacy aCRC, so represent a much-needed additional predictive marker these drugs. <h3>Objective</h3> To examine novel ligand model randomized clinical trial panitumumab, irinotecan,...

10.1001/jamaoncol.2015.6065 article EN JAMA Oncology 2016-02-12

Increased number of melanocytic nevi is a potent melanoma risk factor. We have carried out large population-based case-control study to explore the environmental and genetic determinants relationship with risk.We report nevus phenotype in relation differing patterns sun exposure, inherited variation at loci shown recent genome-wide association studies be genes, risk.Increased numbers were associated holiday particularly on intermittently sun-exposed body sites (test for P(trend) < 0.0001)....

10.1158/1055-9965.epi-10-0233 article EN Cancer Epidemiology Biomarkers & Prevention 2010-08-01

The aims of this study were to investigate the role vascular invasion (blood and lymphatic), vessel density presence tumour-associated macrophages as prognostic markers in 202 cutaneous melanoma patients. Sections primary stained with lymphatic-specific antibody D2-40 assess lymphatic intratumoural peritumoural areas; an against endothelial marker CD34 was used determine blood density, CD68 macrophage counts. Immunohistochemically determined (combined lymphatic) compared that using...

10.1038/modpathol.2011.182 article EN cc-by-nc-nd Modern Pathology 2011-11-11

MicroRNAs (miRNAs) are involved in post-transcriptional regulation of gene expression through binding to messenger RNAs (mRNA) thereby promoting mRNA degradation or altered translation. A single-nucleotide polymorphism (SNP) located within a miRNA-binding site could thus alter translation and influence cancer risk treatment response. The common SNPs the 3′-untranslated regions 20 DNA repair genes were analysed for putative sites using bioinformatics algorithms, calculating difference Gibbs...

10.1093/carcin/bgr300 article EN cc-by-nc Carcinogenesis 2011-12-12

Gene expression studies in melanoma have been few because tumors are small and cryopreservation is rarely possible. The purpose of this study was to evaluate the Illumina DASL Array Human Cancer Panel for gene formalin-fixed primary identify prognostic biomarkers.Primary from two were sampled using a tissue microarray needle. Study 1: 254 cohort recruited 2000 2006. 2: 218 case-control patients undergoing sentinel node biopsy.RNA obtained 76% blocks; 1.4% samples failed analysis (transcripts...

10.1158/1078-0432.ccr-09-1631 article EN Clinical Cancer Research 2009-11-04

Abstract The CAPP2 trial investigated the long-term effects of aspirin and resistant starch on cancer incidence in patients with Lynch syndrome (LS). Participants LS were randomized double-blind to 30 g (RS) daily or placebo for up 4 years. We present outcomes based planned 10-year follow-up from recruitment, supplemented by National Cancer Registry data 20 years England, Wales, Finland. Overall, 463 participants received RS 455 placebo. After follow-up, there was no difference colorectal (n...

10.1158/1940-6207.capr-22-0044 article EN cc-by-nc-nd Cancer Prevention Research 2022-07-25

To optimise predictive models for sentinal node biopsy (SNB) positivity, relapse and survival, using clinico-pathological characteristics osteopontin gene expression in primary melanomas. A comparison of the SNB positive negative cases was carried out 561 melanoma patients. In 199 patients, formalin-fixed tumours studied Illumina's DASL assay. cross validation approach used to test prognostic receiver operating characteristic curves were produced. Independent predictors positivity Breslow...

10.1038/sj.bjc.6605849 article EN cc-by-nc-sa British Journal of Cancer 2010-09-21
Coming Soon ...